Actinogen Medical’s Capital Raise Oversubscribed
Company Announcements

Actinogen Medical’s Capital Raise Oversubscribed

Actinogen Medical Limited (AU:ACW) has released an update.

Actinogen Medical Limited has successfully completed an oversubscribed entitlement offer, raising $8.9 million to fund the progression of its XanaMIA Alzheimer’s disease trial and for general working capital. Shareholders demonstrated strong support with no shortfall in acceptances for shares, with new share trading to commence by June 6, 2024. The raised capital underscores shareholder confidence in the potential of Actinogen’s lead compounds in ongoing clinical trials.

For further insights into AU:ACW stock, check out TipRanks’ Stock Analysis page.

Looking for more investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Optimize your mobile reading experience. Download the TipRanks App today!